Archive \ Volume.12 2021 Issue 4

An Overview on Non-invasive Assessment of Cirrhosis

Ahmed Elsherbiny Shahin , Sultan Nahar Alshmmary , Norah Sulaiman Aljabarah , Abdulmajeed Mohammed Alshammari , Khalid Melih Alshammari , Reem Saud Alabedah , Hussain Khalid Almudayni , Dhari Abdulkarim Saleh Alquwaiay , Abdulaziz Muflih Alghaithi
Abstract

Chronic liver disease is a long-term degradation of liver processes, such as the production of clotting factors and the detoxification of toxic metabolic products. It is a constant cycle of liver parenchyma inflammation, destruction, and regeneration that leads to cirrhosis and fibrosis. the last phase of it being cirrhosis, characterized by distortion of hepatic architecture, the development of extensive nodules. Additionally, it is mostly in a cirrhotic liver that there is a development of hepatocellular carcinoma (HCC). Cirrhosis and HCC are responsible for 3.5% of all fatalities globally. Nevertheless, cirrhosis may be prevented since the diseases that most often cause it to develop slowly and can be prevented and treated. Therefore, early detection and adequate evaluation of the disease are important for preventing the progress or even reversing some of the effects of the disease. To provide an adequate review discussing the evaluation of chronic liver disease cases and cirrhosis in particular. The following keys were used in the mesh of the PubMed database for the choosing of articles. Characteristic findings on clinical examination, laboratory testing, and auxiliary studies are used to diagnose the disease. If firmly established through imaging investigations and medical symptoms that cirrhosis has been diagnosed, a liver biopsy is unnecessary, if not even contraindicated.



How to cite:
Vancouver
Shahin A E, Alshmmary S N, Aljabarah N S, Alshammari A M, Alshammari K M, Alabedah R S, et al. An Overview on Non-invasive Assessment of Cirrhosis. Arch. Pharm. Pract. 2021;12(4):42-8. https://doi.org/10.51847/zpADEWrmGX
APA
Shahin, A. E., Alshmmary, S. N., Aljabarah, N. S., Alshammari, A. M., Alshammari, K. M., Alabedah, R. S., & et al (2021). An Overview on Non-invasive Assessment of Cirrhosis. Archives Of Pharmacy Practice, 12(4),42-48. https://doi.org/10.51847/zpADEWrmGX

Download Citation
References

1.        Heidelbauch J, Bruderly M. Cirrhosis and chronic liver failure: part I Diagnosis and evaluation. http://hdl.handle.net/10234/187818

2.        Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371(9615):838-51. doi:10.1016/s0140-6736(08)60383-9.

3.        Martin P. The oxford textbook of clinical hepatology. doi:10.1016/s0016-5085(00)70235-6.

4.        Williams R. Sherlock's disease of the liver and biliary systems. Clin Med. 2011;11(5):506. doi:10.7861/clinmedicine.11-5-506.

5.        Desmet VJ, Roskams T. Cirrhosis reversal: a duel between dogma and myth. J Hepatol. 2004;40(5):860-7. doi:10.1016/j.jhep.2004.03.007.

6.        Wanless IR, Nakashima E, Sherman M. Regression of human cirrhosis: morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med. 2000;124(11):1599-607. doi:10.5858/2000-124-1599-rohc.

7.        Schölmerich J, Holstege A. Aetiology and pathophysiology of chronic liver disorders. Drugs. 1990;40(3):3-22. doi:10.2165/00003495-199000403-00003.

8.        Asrani SK, Larson JJ, Yawn B, Therneau TM, Kim WR. Underestimation of liver-related mortality in the United States. Gastroenterology. 2013;145(2):375-82. doi:10.1053/j.gastro.2013.04.005.

9.        Mokdad AA, Lopez AD, Shahraz S, Lozano R, Mokdad AH, Stanaway J, et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med. 2014;12(1):1-24. doi:10.1186/s12916-014-0145-y.

10.      Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095-128.  doi:10.1016/s0140-6736(12)61728-0.

11.      Dondog B, Lise M, Dondov O, Baldandorj B, Franceschi S. Hepatitis B and C virus infections in hepatocellular carcinoma and cirrhosis in Mongolia. Eur J Cancer Prev. 2011;20(1):33-9. doi:10.1097/cej.0b013e32833f0c8e.

12.      Stepanova M, De Avila L, Afendy M, Younossi I, Pham H, Cable R, et al. Direct and indirect economic burden of chronic liver disease in the United States. Clin Gastroenterol Hepatol. 2017;15(5):759-66. doi:10.1016/j.cgh.2016.07.020.

13.      Peery AF, Crockett SD, Barritt AS, Dellon ES, Eluri S, Gangarosa LM, et al. Burden of gastrointestinal, liver, and pancreatic diseases in the United States. Gastroenterology. 2015;149(7):1731-41. doi:10.1053/j.gastro.2015.08.045.

14.      Wiegand J, Berg T. The etiology, diagnosis and prevention of liver cirrhosis: part 1 of a series on liver cirrhosis. Dtsch Arztebl Int. 2013;110(6):85. doi:10.3238/arztebl.2013.0085.

15.      Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli‐Vergani G, Vergani D, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51(6):2193-213. doi:10.1002/hep.23584.

16.      Chen CF, Lee WC, Yang HI, Chang HC, Jen CL, Iloeje UH, et al. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma. Gastroenterology. 2011;141(4):1240-8. doi:10.1053/j.gastro.2011.06.036.

17.      Berg T. Diagnostik bei erhöhten Leberwerten. Gastroenterologe. 2009;4(6):557-72. doi:10.1007/s11377-009-0340-0.

18.      Tannapfel A, Dienes HP, Lohse AW. The indications for liver biopsy. Dtsch Arztebl Int. 2012;109(27-28):477. doi:10.3238/arztebl.2012.0477.

19.      Schirmacher P, Fleig WE, Tannapfel A, Langner C, Dries V, Terracciano L, et al. Bioptische Diagnostik der chronischen HepatitisErgebnisse einer evidenzbasierten Konsensuskonferenz der Deutschen Gesellschaft fr Pathologie (DGP), der Deutschen Gesellschaft fr Verdauungs-und Stoffwechselkrankheiten (DGVS) und des Kompetenznetzes Hepatitis (HepNet). Pathologe. 2004;5(25):337-48. doi:10.1007/s00292-004-0692-7.

20.      Castera L, Pinzani M. Biopsy and non-invasive methods for the diagnosis of liver fibrosis: does it take two to tango?. Gut. 2010;59(7):861-6. doi:10.1136/gut.2010.214650.

21.      Poynard T, Halfon P, Castera L, Munteanu M, Imbert-Bismut F, Ratziu V, et al. Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Clin Chem. 2007;53(9):1615-22. doi:10.1373/clinchem.2007.085795.

22.      Sebastiani G, Castera L, Halfon P, Pol S, Mangia A, Di Marco V, et al. The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non‐invasive fibrosis biomarkers: an international study of 2411 cases. Aliment Pharmacol Ther. 2011;34(10):1202-16. doi:10.1111/j.1365-2036.2011.04861.x.

23.      Martínez-Noguera A, Montserrat E, Torrubia S, Villalba J. Doppler in hepatic cirrhosis and chronic hepatitis. Semin Ultrasound CT MRI. 2002;23(1):19-36. doi:10.1016/s0887-2171(02)90027-2.

24.      Lencioni R, Cioni D, Bartolozzi C. Tissue harmonic and contrast-specific imaging: back to gray scale in ultrasound. Eur Radiol. 2002;12(1):151-65. doi:10.1007/s003300101022.

25.      Burrel M, Llovet JM, Ayuso C, Iglesias C, Sala M, Miquel R, et al. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology. 2003;38(4):1034-42. doi:10.1002/hep.1840380430.

26.      Qayyum A, Goh JS, Kakar S, Yeh BM, Merriman RB, Coakley FV. Accuracy of liver fat quantification at MR imaging: comparison of out-of-phase gradient-echo and fat-saturated fast spin-echo techniques—initial experience. Radiology. 2005;237(2):507-11. doi:10.1148/radiol.2372040539.

27.      Ziol M, Handra‐Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology. 2005;41(1):48-54. doi:10.1002/hep.20506.

28.      Gerstenmaier JF, Gibson RN. Ultrasound in chronic liver disease. Insights Imaging. 2014;5(4):441-55. doi:10.1007/s13244-014-0336-2.

29.      Ibrahim AA, Abdelbasset WK. The role of physical exercise in treating people with non-alcoholic fatty liver disease. J Adv Pharm Edu Res. 2020;10(2):64-70.

30.      Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140(1):124-31. doi:10.1053/j.gastro.2010.09.038.

31.      Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011;9(6):524-30. doi:10.1016/j.cgh.2011.03.020

32.      Ludwig J, Viggiano TR, Mcgill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55(7):434-8. https://europepmc.org/article/med/7382552

33.      Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94(9):2467-74. doi:10.1111/j.1572-0241.1999.01377.x.

34.      Gebo KA, Herlong HF, Torbenson MS, Jenckes MW, Chander G, Ghanem KG, et al. Role of liver biopsy in management of chronic hepatitis C: a systematic review. Hepatology. 2002;36(S1):S161-72. doi:10.1053/jhep.2002.36989.

35.      Seeff LB, Everson GT, Morgan TR, Curto TM, Lee WM, Ghany MG, et al. Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol. 2010;8(10):877-83. doi:10.1016/j.cgh.2010.03.025.

36.      Choong CC, Venkatesh SK, Siew EP. Accuracy of routine clinical ultrasound for staging of liver fibrosis. J Clin Imaging Sci. 2012;2. doi:10.4103/2156-7514.101000.

37.      Colli A, Fraquelli M, Andreoletti M, Marino B, Zuccoli E, Conte D. Severe liver fibrosis or cirrhosis: accuracy of US for detection—analysis of 300 cases. Radiology. 2003;227(1):89-94. doi:10.1148/radiol.2272020193.

38.      Gibson RN. Ultrasound evaluation of hepatic vein morphology: a promising simple diagnostic tool?. Imaging Med. 2011;3(2):145. doi:10.2217/iim.11.3.

39.      Sangster GP, Previgliano CH, Nader M, Chwoschtschinsky E, Heldmann MG. MDCT imaging findings of liver cirrhosis: spectrum of hepatic and extrahepatic abdominal complications. HPB Surg. 2013;2013. doi:10.1155/2013/129396.

40.      Itai Y, Murata S, Kurosaki Y. Straight border sign of the liver: spectrum of CT appearances and causes. Radiography. 1995;15(5):1089-102. doi:10.1148/radiographics.15.5.7501852.

41.      Ohtomo K, Baron RL, Dodd 3rd GD, Federle MP, Miller WJ, Campbell WL, et al. Confluent hepatic fibrosis in advanced cirrhosis: appearance at CT. Radiology. 1993;188(1):31-5. doi:10.1148/radiology.188.1.8511316.

42.      Ohtomo K, Baron RL, Dodd 3rd GD, Federle MP, Ohtomo Y, Confer SR. Confluent hepatic fibrosis in advanced cirrhosis: evaluation with MR imaging. Radiology. 1993;189(3):871-4. doi:10.1148/radiology.189.3.8234718.

43.      Gupta AA, Kim DC, Krinsky GA, Lee VS. CT and MRI of cirrhosis and its mimics. AJR Am J Roentgenol. 2004;183(6):1595-601. doi:10.2214/ajr.183.6.01831595.

44.      Dodd 3rd GD, Baron RL, Oliver 3rd JH, Federle MP. Spectrum of imaging findings of the liver in end-stage cirrhosis: Part II, focal abnormalities. AJR Am J Roentgenol. 1999;173(5):1185-92. doi:10.2214/ajr.173.5.10541086.

45.      Martí-Bonmatí L, Delgado F. MR imaging in liver cirrhosis: classical and new approaches. Insights Imaging. 2010;1(4):233-44. doi:10.1007/s13244-010-0034-7.

46.      Talwalkar JA, Yin M, Fidler JL, Sanderson SO, Kamath PS, Ehman RL. Magnetic resonance imaging of hepatic fibrosis: emerging clinical applications. Hepatology. 2008;47(1):332-42. doi:10.1002/hep.21972.

47.      Taouli B, Ehman RL, Reeder SB. Advanced MRI methods for assessment of chronic liver disease. AJR Am J Roentgenol. 2009;193(1):14. doi:10.2214/ajr.09.2601